Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-104 in Advanced Solid Tumors
NCT07814248Phase 1Recruiting
- Sponsor
- TwoStep Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of TS-104 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer and 3 more (3 arms), sponsored by TwoStep Therapeutics. Primary endpoints: Adverse Events up to 26 months and Dose Limiting Toxicities up to 28 days. Started Sep 2026; status: recruiting.
02
Drugs
TS-104
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)esophageal cancerendometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT07814248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814248.